Skip to main content

copanlisib

Generic: COPANLISIB DIHYDROCHLORIDE·Brand: ALIQOPA, Aliqopa

copanlisib: 4 clinical trials tracked.

copanlisib evidence translation

What we can confirm

4 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about copanlisib, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence8 indications · 2 study sponsors
Clinical Trials (4)

A Phase Ib/II Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

NCT04253262·Phase 1/Phase 2

Primary endpoint: Maximum Tolerated Dose

Interventionalopen13 targetStarted 2020-04Completion 2027-012 sites · United StatesBrown University

A Phase I Study of PI3Kα,δ Inhibitor Copanlisib in Combination With PD-1 Antagonist Nivolumab in Patients With Transformed Chronic Lymphocytic Leukemia (Richter's Transformation) or Non-Hodgkin Lymphoma

NCT03884998·Phase 1
Active, not recruiting

Primary endpoint: Incidence of dose-limiting toxicities of copanlisib in combination with nivolumab

Interventionalopen27 enrolledStarted 2019-07Completion 2026-113 sites · United StatesCity of Hope Medical Center

Phase Ib Study of Copanlisib in Combination With Nivolumab or With Nivolumab and Ipilimumab

NCT03502733·Phase 1·ENTA
Active, not recruiting

Primary endpoint: Recommended phase 2 dose of copanlisib and nivolumab combination

Interventionalopen64 targetStarted 2018-08Completion 2026-073 sites · United StatesNational Cancer Institute (NCI)

Molecular Analysis for Therapy Choice (MATCH)

NCT02465060·Phase 2·ADMA
Active, not recruiting

Primary endpoint: Objective response rate (ORR)

Interventionalopen6,452 targetStarted 2015-08Completion 2026-1250 sites · United StatesNational Cancer Institute (NCI)